O 1 curitd

sensations are understood to mean more or less painful sensations experienced in an area of the skin, such as prickling, tingling, itching or pruritus, burning, inflammation, discomfort, tightness, and the like.--

Please replace paragraph 11 as follows.

B2

--An intolerant skin is a skin which reacts by sensations of inflammation or of tightness, by pruritus, that is to say by itching or prickling, by tingling and/or red blotches, to different factors such as the environment, emotions and foods. In general, these signs are associated with erythema and with a skin with or without sores. --

Please replace paragraph 12 as follows.

--"Sensitive" scalps have a more unequivocal symptomatology: the sensations of pruritus and/or of prickling and/or of inflammation are essentially triggered by local factors such as rubbing, soap, surfactants, hard water with a high chalk concentration, shampoos or lotions. These sensations are also sometimes triggered by factors such as the environment, emotions and/or foods. Erythema and hyperseborrhoea of the scalp as well as a dandruff state are frequently associated with the above signs.--

Please replace paragraph 13 as follows.

--Moreover, in some anatomical regions, such as the major folds (inguinal, genital, axillary, popliteal, anal and inframammary regions, bend of the elbow) and the feet,

82 Corital

sensitive skin manifests itself in pruriginous sensations and/or dysaesthesic sensations (inflammation, prickling) associated especially with sweating, with rubbing, with wool, with surfactants, with hard water with a high chalk concentration and/or with temperature changes.--

Please replace paragraph 20 as follows.

B3

--In addition, the Applicants found that the addition of interleukin-1 antagonists and/or of TNF-alpha antagonists to cosmetic, pharmaceutical or dermatological compositions for topical application containing irritant products (alpha-hydroxy acids, retinoids, benzoyl peroxide, etc.) also enabled the irritation reactions usually caused by these products to be decreased or even eliminated. These irritation reactions manifest themselves within moments following application, in dysaesthesic sensations (inflammation, burning, itching or pruritus sensations, prickling sensations, tightness, etc.), and/or in red blotches, and/or in edema. These irritation states may also manifest themselves some time after application, in the persistence, appearance or reappearance of the above-mentioned dysaesthesic sensations and/or in red blotches and/or scales; these skin irritation states may assume the appearance of plaques of cutaneous xerosis and/or sores.--

Please replace paragraph 24 as follows.

BH

--The subject of the present invention is also the use in a topical composition of at least one compound chosen from interleukin-1 antagonists, TNF-alpha antagonists and combinations thereof, for preventing and/or combating skin irritations and/or sores and/or erythema and/or sensations of inflammation and/or of dysaesthesia and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae.--

Please replace paragraph 26 as follows.

B5

--The subject of the present invention is also the use in a topical composition of at least one constituent chosen from histamine antagonists and combinations thereof, for preventing and/or combating skin irritations and/or sores and/or sensations of inflammation and/or of dysaesthesia and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae.--

IN THE ABSTRACT:

Kindly replace the Abstract with the attached substitute Abstract.

IN THE CLAIMS:

Kindly cancel claims 2 and 11 without prejudice to or disclaimer of the subject matter therein.

Kindly replace claims 1 and 10 as follows: